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From 1 September 2015 through 31 January 2016, we enrolled 2068 children 
6 months to 17 years of age admitted to hospital with a febrile acute respiratory infec-
tion in our test- negative study. Information on receipt of 2015–16 northern hemi-
sphere inactivated influenza vaccination was elicited from parents or legal guardians. 
Using conditional logistic regression adjusting for age and matching on calendar time, 
we estimated influenza vaccine effectiveness against hospitalization with influenza A 
or B to be 79.2% (95% confidence interval: 42.0%–92.4%). Annual influenza vaccina-
tion should be more widely used in children in Hong Kong.
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1  | INTRODUCTION
Influenza viruses circulate each year, causing a considerable burden 
to public health. Children typically face the greatest risk of influenza 
virus infection among all age groups in a population,1 and young chil-
dren have high rates of hospitalizations associated with influenza.2,3 
Influenza vaccination is the most effective measure to prevent infec-
tion and recommended by the World Health Organization for many 
high- risk groups including young children from 6 to 59 months of 
age.4 In Hong Kong, a subtropical city on the south coast of China, 
all children between 6 months and 6 years of age and children 
6 years of age or above with an underlying condition associated 
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with an increased risk for influenza complications are recommended 
to receive influenza vaccination each year.5 The Hong Kong gov-
ernment provides a subsidy for influenza vaccination for children 
between 6 months and 6 years of age and older children from low- 
income families, while children between 6 months and 17 years of 
age with an underlying medical condition can receive free influenza 
vaccination.6
It is informative to evaluate influenza vaccination effectiveness 
(VE) each season to confirm that vaccination is providing adequate 
protection, to inform risk communication and to provide evidence 
for vaccination strategies and other public health measures.7 Timely 
interim, or mid- season, estimates of influenza VE can be particularly 
useful to guide resource allocation or implement additional preventive 
measures if VE is low.8
2  | METHODS
2.1 | Study design
We used the test- negative study design, which is a type of case–
control design, to estimate influenza VE.6,7,9–11 We enrolled chil-
dren admitted to Queen Mary Hospital 1 of 2 public hospitals 
with inpatient paediatric services on Hong Kong Island, and the 
Princess Margaret Hospital and Yan Chai Hospital network which 
are 2 of the 3 public hospitals in the West Kowloon district with 
inpatient paediatric services. The same study protocol was used 
in each hospital. Children 6 months to 17 years of age admitted 
to the general wards of these hospitals with a febrile acute res-
piratory infection, defined as fever measured ≥38°C with any res-
piratory symptom such as cough, runny nose or sore throat, were 
eligible for inclusion in this study. Children with risk factors for 
potentially severe respiratory infections such as prematurity or 
chronic lung disease were not excluded. Nasopharyngeal aspirates 
were obtained from all patients and tested for influenza A and B 
virus by direct immunofluorescence assay (for rapid diagnosis) 
followed by reverse transcriptase polymerase chain reaction for 
seasonal influenza A and B viruses using laboratory methods as 
previously described.6,11
Influenza vaccination history within 6 months of hospitalization 
was elicited from the parents or legal guardians of patients using a 
standardized questionnaire administered by research personnel. 
Vaccinated children were those who had received influenza vaccina-
tion within the 6 months prior to admission in a regimen and dosage 
appropriate for age and influenza vaccination history according to 
the recommendations of the Advisory Committee on Immunization 
Practices, with the last dose more than 2 weeks before hospitaliza-
tion.12 Children who should receive 2 doses of influenza vaccination, 
but only received 1 dose or were vaccinated within 2 weeks of hospi-
talization were categorized as unvaccinated. The northern hemisphere 
formulation of trivalent and quadrivalent inactivated influenza vac-
cines were used during our study period. Analysis was performed by 
R 3.1.1.
2.2 | ETHICAL APPROVAL
The study protocol was approved by the Institutional Review Board 
of the University of Hong Kong and that of the Kowloon West Cluster 
Research Ethics Committee which waived the need for written con-
sent as viral investigation was a routine diagnostic test carried out 
as part of routine care, any patient information was delinked from 
individual patient identification to maintain patient confidentiality and 
participation by responding to the questionnaire was voluntary and 
indicative of consent.
2.3 | Statistical analysis
Following the analytic approach used in previous years,6,11 we used 
conditional logistic regression models for influenza status versus vac-
cination status, adjusting for age and age squared, and matching on 
calendar time. We matched for calendar time because influenza vac-
cine coverage changes over time during prolonged periods of influenza 
activity in Hong Kong.6,11 VE was estimated as one minus the adjusted 
conditional odds ratio, multiplied by 100%. Statistical analyses were 
performed in R version 3.1.1 (R Foundation for Statistical Computing, 
Vienna, Austria).
3  | RESULTS
We enrolled 2068 children from 1 September 2015 through 31 
January 2016. A small number of children with unknown vaccina-
tion history (n = 8) or unknown laboratory results (n = 11) were 
excluded, leaving data on 2049 children for inclusion in analy-
ses. Of the 2049 children, 59 (2.9%) tested positive for influenza 
A(H1N1), 15 (0.7%) tested positive for influenza A(H3N2), 49 
(2.4%) tested positive for influenza B and the remainder tested 
negative for influenza. The characteristics of enrolled patients 
are shown in Table 1. Patients testing negative for influenza were 
enrolled at fairly constant rates throughout the period, while most 
patients testing positive for influenza were enrolled in January 
2016, with the early part of the influenza season being dominated 
by A(H1N1) (Fig. 1).
We estimated influenza VE to be 79.0% (95% confidence inter-
val, CI: 42.0, 92.4) against any influenza, 82.8% (95% CI: 28.4, 95.9) 
against influenza A and 73.0% (95% CI: −12.8, 93.5) against influ-
enza B among children aged 6 months to 17 years. Age- specific 
estimates of VE overall and by influenza type are shown in Fig. 2. 
We did not have sufficient data to estimate VE against influenza A 
subtypes.
4  | DISCUSSION
Influenza vaccination coverage was only 14% in the hospitalized chil-
dren despite government subsidies for younger children and children 
at higher risk of complicated infection. Our preliminary estimates of 
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influenza VE for the 2015–16 northern hemisphere influenza vac-
cine were at the high end of VE against influenza hospitalization 
compared to estimates in the same age group from previous years 
in Hong Kong6,11: VE against overall influenza A or B hospitalization 
was 61.7% (95% CI: 43.0, 74.2) in 2009–2013 and against influenza 
B hospitalization was 47.6% (95% CI: 10.0, 69.4) in 2009–2014.. 
Studies conducted in outpatient settings for all ages reported mod-
est to high early/interim VE estimates: Canada recently reported VE 
of 64% (95% CI: 44–77) against influenza A(H1N1)13; the I- MOVE 
study reported VE of 46.3% (4.9–69.7%) against any influenza14; the 
United States reported an interim estimate of VE of 59%15; and the 
United Kingdom reported an interim estimate of 41.5% against any 
influenza.16
There are some limitations of our study. We estimated VE against 
hospitalization, and this will differ from VE against infection or medi-
cally attended infection if vaccination modifies disease severity.10 In 
a recent review, estimates of VE against hospitalization were very 
similar to estimates of VE against medically attended illness, for 
studies conducted in the same populations, years and age groups.17 
Influenza vaccination history of 6 months was self- reported, and 
misclassification of vaccination status may have biased estimates of 
VE.18 Information was not available on potential confounders such 
as underlying medical conditions. The sample size was large enough 
to confirm statistically significant overall VE, but not sufficient to 
provide precise estimates of VE in some age groups. Finally, our 
interim estimates of VE may differ from the future end- of- season 
estimate, although usually interim estimates are quite similar to final 
end- of- season estimates in test- negative studies.8,19,20 Final esti-
mates for 2015–16 in Hong Kong will be available around the end 
of 2016.
In conclusion, we documented that influenza vaccination was 
associated with good protection against influenza- associated 
TABLE  1 Comparison of cases testing positive for influenza A 
and B and test- negative cases in Hong Kong, 2015–16
Characteristic
Test- positive for 
influenza A or B 
(n = 123) 
N (%)
Test- negative for 
influenza A and B 
(n = 1926)  
N (%) P- valuea
Age group
6 mo–2 y 40 (32.5%) 980 (50.9%) <0.01
3–5 y 39 (31.7%) 570 (29.6%)
6–17 y 44 (35.8%) 376 (19.5%)
Male 77 (62.6%) 1068 (55.5%) 0.15
Receipt of TIV/QIVb 
in the preceding 
6 mo
4/123 (3.3%) 279/1926 (14.5%) <0.01
Breakdown of overall vaccination coverage by age
6 mo–2 y 0/40 (0%) 87/980 (8.9%) 0.09
3–5 y 1/39 (2.6%) 135/570 (23.7%) <0.01
6–17 y 3/44 (6.8%) 57/346 (15.2%) 0.21
Breakdown of vaccines received by vaccine type:
Vaccine type: TIVb 3/4 (75.0%) 127/279 (45.5%) 0.34
Vaccine type: QIVb 0/4 (0%) 65/279 (23.3%) 0.58
Vaccine type: 
unknown
1/4 (25.0%) 87/279 (31.2%) 1.00
aP- values estimated by chi- squared tests and Fisher’s exact test.
bTIV, trivalent inactivated influenza vaccine, QIV, quadrivalent inactivated 
influenza vaccine.
F IGURE  1 Enrolment of children from 1 September 2015 through 31 January 2016 in Hong Kong, classified by laboratory testing result for 
influenza by type/subtype
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hospitalization in children 6 months to 17 years in Hong Kong in this 
interim analysis. Healthcare providers and parents should be encour-
aged to increase influenza vaccination coverage in children in Hong 
Kong.
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